France’s Medical Cannabis Trial: 3% Serious Adverse Events in 3,164 Patients Over Three Years

During the experimentation, 3% of patients treated with MC experienced at least one serious ADR. The safety profile was dominated by neurological, gastrointestinal, and psychiatric ADRs. Only one case of MC misuse was identified with inflorescences. This study is observational and non-comparative and cannot provide a comprehensive assessment of the risk associated with MC use.

Read More

Canada’s Cannabis Safety Surveillance System: What Six Years of Adverse Reaction Reports Reveal

Overall, individuals reporting an adverse reaction to a cannabis product (n=698) were 56.0 ยฑ 20.0 years of age. 45.4% of reporting individuals were female, and 67.5% of individuals self-reported using cannabis for medical purposes… Most cases were reported as serious (62.3%), citing ‘other medically important condition’ as the primary reason for seriousness (58.6%), and 68.8% of all cases involved cannabis extracts.

Read More